A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease

J. Snow, Barry; L. Rolfe, Fiona; M. Lockhart, Michelle; M. Frampton, Christopher; D. O'Sullivan, John; Fung, Victor; A.J. Smith, Robin; P. Murphy, Michael; M. Taylor, Kenneth; behalf of the Protect Study Group, On

doi:10.1002/mds.23148

Public

A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease

Shared by NobleBlocks on Aug 15, 2010 • 12:00 AM UTC

Authors:

Barry J. Snow

Fiona L. Rolfe

Michelle M. Lockhart

Abstract

Abstract Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative dam...

Discussions